Stock Name | LTP | Change (%) | Sub-sector | Sector P/E | Market Cap | Volume | 52 Weeks High | 52 Weeks Low | 1M Return | 3M Return | 1Yr Return | 3Yr Return | 5Yr Return | Dividend (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unichem Laboratories Ltd | ₹572.70 | +20.00 | Pharmaceuticals & Drugs | 65.1640 | ₹3,354.13 | 35,35,392 | ₹657.95 | ₹278.20 | +33.72 | +44.93 | -20.33 | +24.80 | +44.97 | - |
| Orchid Pharma Ltd | ₹1,002.25 | +8.39 | Pharmaceuticals & Drugs | 65.1640 | ₹4,699.89 | 32,59,822 | ₹1,094.00 | ₹480.00 | +9.74 | +71.95 | +27.36 | +82.29 | +37.65 | - |
| Maitreya Medicare Limited | ₹140.90 | +5.94 | Hospital & Healthcare Services | 65.1640 | ₹95.47 | 2,800 | ₹292.95 | ₹133.00 | -10.37 | -23.07 | -46.02 | -8.77 | - | - |
| Hikal Ltd | ₹228.78 | +5.23 | Pharmaceuticals & Drugs | 65.1640 | ₹2,684.87 | 1,01,88,371 | ₹355.00 | ₹146.25 | +20.93 | +24.43 | -36.80 | -27.05 | -57.51 | - |
| Ngl Fine Chem Ltd | ₹3,246.60 | +4.99 | Pharmaceuticals & Drugs | 65.1640 | ₹1,910.06 | 15,496 | ₹3,319.80 | ₹1,175.50 | +16.55 | +32.64 | +148.94 | +60.50 | +65.46 | - |
| Holmarc Opto Mechatronics Ltd | ₹103.40 | +4.97 | Medical Equipment/Supplies/Accessories | 65.1640 | ₹98.99 | 2,250 | ₹134.30 | ₹60.05 | -7.94 | +28.67 | -23.85 | +43.80 | - | - |
| Ind Swift Laboratories Ltd | ₹225.47 | +4.80 | Pharmaceuticals & Drugs | 65.1640 | ₹1,872.72 | 49,30,326 | ₹225.99 | ₹87.15 | +37.27 | +43.17 | +82.05 | +156.59 | +121.23 | - |
| Amanta Healthcare Ltd Share Price | ₹188.00 | +4.56 | Pharmaceuticals & Drugs | 65.1640 | ₹706.50 | 4,68,054 | ₹179.80 | ₹92.00 | +37.41 | +64.31 | +26.84 | +26.84 | - | - |
| Unihealth Hospitals Ltd | ₹720.00 | +4.56 | Hospital & Healthcare Services | 65.1640 | ₹1,094.87 | 57,500 | ₹688.60 | ₹133.65 | +49.02 | +66.45 | +296.89 | +417.74 | - | - |
| Chd Chemicals Limited | ₹243.25 | +3.91 | Hospital & Healthcare Services | 65.1640 | ₹572.42 | 69,600 | ₹358.00 | ₹185.40 | -1.01 | -13.28 | +14.61 | +35.04 | - | - |
Shares of companies providing medical services, diagnostic testing, healthcare equipment, or health-related technology – listed on Indian stock exchanges.
Hospital chains running multi-specialty and single-specialty facilities, diagnostic labs and pathology chains, medical device and equipment manufacturers, pharmacy chains, and healthcare IT companies all fall under this sector. Each earns differently — hospitals on bed occupancy and procedure volumes, diagnostics on test volumes, device companies on product sales.
Hospitals earn from inpatient admissions, surgeries, outpatient consultations, and pharmacy sales within their facility. Diagnostics companies earn per test conducted. Medical device companies earn on product margins and after-sales service contracts. The recurring, non-discretionary nature of most healthcare spending is what makes these companies relatively resilient during economic downturns.
Hospital Stocks in India: Multi-specialty and super-specialty hospital chains account for most of the market cap in this sector. They earn from inpatient care, surgery volumes, and increasingly from international medical tourism. Scale matters here — larger hospitals spread fixed costs across more patients, improving margins.
Diagnostic and Pathology Stocks: Chains like standalone labs and integrated diagnostics networks earn from test volumes. Home collection, digital reports, and standardised quality protocols have helped branded diagnostics chains gain share from local labs across India’s smaller cities.
Medical Devices and Equipment: Manufacturers and distributors of surgical instruments, imaging systems, and other medical hardware. Domestic manufacturing and importer mix with a margin depending on the product mix and post-sales service intensity.
Healthcare IT and Support Services: Hospital management software, telemedicine platforms, and healthcare data services — a smaller but growing part of the listed healthcare universe as digital adoption in hospitals accelerates.
Rising Healthcare Spending: Per capita healthcare spending in India is rising — both out of pocket and through insurance. As household income grows, people spend more on better diagnostic and treatment options.
Underpenetrated Hospital Beds and Diagnostics: India has significantly fewer hospital beds per thousand people than most comparable countries. Closing even a fraction of that gap requires years of sustained capacity addition — a structural demand driver for hospital and healthcare service companies.
Health Insurance Expansion: More insured patients means higher affordability for higher-margin procedures at hospitals. Insurance penetration is still low but growing, directly expanding the paying patient base for healthcare companies.
Medical Tourism: India attracts patients from the Middle East, Africa, and Southeast Asia for complex, affordable procedures. Hospital companies with strong international referral networks earn premium revenues from medical tourists.
Occupancy Rates for Hospital Stocks: Hospital occupancy tells you how efficiently the facility is using its fixed assets. High and improving occupancy — above 60-65% — suggests strong demand at a specific location. New hospitals drag down group-level occupancy until they ramp up.
ARPU and Revenue Per Patient: Average revenue per occupied bed is the key metric for hospital profitability. Rising ARPU indicates a shift toward more complex, higher-margin procedures or premium patient mix — both positive for earnings.
Debt and Expansion Plans: Hospital expansion is capital-intensive. Check the debt load and what expansion is being funded by — internal cash flows are safer than heavily leveraged growth. New beds take two to four years to reach operating maturity.
Regulatory Approvals: NABH accreditation, regulatory licensing for new facilities, and government pricing caps on certain procedures all affect hospital earnings. Check regulatory status before taking a view on new hospital additions.
Government price regulation on drugs and certain medical procedures can compress margins without warning. Private hospitals face periodic scrutiny on billing practices. Diagnostic companies face price pressure as volume players compete aggressively on test pricing. Capital-intensive expansion plans carry execution risk — cost overruns and slower-than-expected ramp-ups are common. Healthcare companies also face rising competition from new entrants backed by private equity.
India’s healthcare infrastructure gap will take decades to close — that makes the structural demand story for hospital, diagnostics, and medical services companies unusually durable. Tier 2 and tier 3 city expansion is the next growth frontier for most listed chains. Healthcare IT and digital health are adding a new layer of earnings potential to the sector over the medium term.
Healthcare sector stocks span hospitals, diagnostics, devices, and services — each with different margins and demand drivers. The sector’s non-discretionary demand and structural underpenetration make it one of the more defensible areas of the Indian equity market over the long term. Compare companies on the page above before making any allocation decision.
Disclaimer: The information provided is not intended to be investment advice and should not be relied upon as such. There are Market risk, Regulatory risk and Sector risk in Healthcare stocks. Past performance is not indicative of future results. Check with a financial advisor before making any investment decisions.
Shares of companies providing hospital services, diagnostics, medical devices, or healthcare IT — listed on NSE and BSE.
Listed hospital chains operating multi-specialty or super-specialty facilities, tracked on occupancy rates, ARPU, and bed addition pipeline.
More defensive than most sectors, since healthcare demand doesn't disappear in a downturn — but individual companies carry execution and regulatory risk that varies significantly.
Track occupancy for hospitals, test volume growth for diagnostics, revenue per patient, debt levels relative to cash generation, and expansion pipeline maturity.